All In Biotech

Drug Trial Radar · NCT05795192

SB17170 Phase1 Trial in Healthy Volunteer

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect, and Ethnicity Effect of SB17170 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

May 24, 2023

Primary completion

Feb 29, 2024

Study completion Mar 15, 2024

Sponsor

Lead sponsor
SPARK BiopharmaIndustry
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults. The main questions it aims to answer are the safety, tolerability, and PK characteristics of SB17170 in healthy adults.

Conditions

  • Safety Issues
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics

Interventions

  • SB17170Drug

    Taking SB17170 orally once a day

  • PlaceboDrug

    Taking Placebo orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: From Day 1 to Day 7 for Single dose, From Day 1 to Day 9 for Multiple dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.